Skip to main content

Table 5 Incremental Cost-Effectiveness Ratios Comparing Three Strategies in China and the USA

From: Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis

  China USA
Full-dose sorafenib vs TACE Dose-adjusted sorafenib vs full-dose sorafenib Full-dose sorafenib vs TACE Dose-adjusted sorafenib vs full-dose sorafenib
Incremental cost per person ($) 6061.73 -6215.23 −60,870.43 −10,812.73
Incremental QALYs per person (years) 0.060 0.047 0.060 0.047
Incremental cost per QALY (ICER, $) 101,028.83 −132,238.94 −1,014,507.20 −230,058.09